MariTide Australia: What the Research Shows
MariTide, also known as maridebart cafraglutide or AMG 133, is an investigational Amgen candidate drawing heavy interest across the 2026 metabolic pipeline. This page explains in neutral terms what it is, how its mechanism is described in the literature, and its current status in Australia. General information only, not legal or medical advice.
Quick answer: what is MariTide?
MariTide is the working name for maridebart cafraglutide, an investigational molecule developed by Amgen and also referred to by its earlier development code AMG 133. It is not a simple peptide. It is described in the scientific literature as a bispecific antibody-peptide conjugate, meaning a monoclonal antibody component joined to peptide components by amino acid linkers.
As of 2026 it is an investigational candidate in clinical development. It is not approved by the Therapeutic Goods Administration and does not appear on the Australian Register of Therapeutic Goods. In an Australian context it is discussed here for research and educational purposes only.
Investigational. Not TGA-approved. Not on the ARTG. Referenced here for research and educational context only, with no therapeutic, efficacy, or dosing claims.
What MariTide actually is
MariTide is the shorthand brand-style name Amgen uses for maridebart cafraglutide. The earlier development designation AMG 133 appears throughout the published research and clinical trial records. All three names refer to the same investigational molecule.
It is important to describe the molecule accurately. It is not a standalone peptide. Published descriptions characterise it as a fully human monoclonal antibody that is conjugated to peptide components, giving a single large bispecific molecule. Because of this antibody-peptide conjugate structure, it is often grouped separately from the smaller peptide candidates that dominate much of the metabolic research conversation.
Names and identifiers
- MariTide, the Amgen working name
- Maridebart cafraglutide, the international non-proprietary style name
- AMG 133, the earlier Amgen development code
How the mechanism is described
In neutral mechanistic terms, the published literature describes MariTide as acting on two different incretin receptor pathways at once. One component is reported to act as an antagonist at the glucose-dependent insulinotropic polypeptide receptor, often written as the GIP receptor or GIPR. The other component is reported to act as an agonist at the glucagon-like peptide-1 receptor, written as the GLP-1 receptor or GLP-1R.
The design rationale cited in the research is drawn partly from human genetics, where certain loss-of-function variants in the GIP receptor have been associated with differences in body mass. This is presented in the literature as scientific background only. It is not a claim about any outcome in people using this molecule.
Descriptions here summarise how researchers characterise the molecule. They are not statements that any particular effect will occur in any individual.
How it differs from other pipeline approaches
MariTide is frequently contrasted with dual-agonist candidates in the same broad research area. The key mechanistic difference discussed in the literature concerns how each candidate treats the GIP receptor.
Some well-known dual molecules are described as agonists at both the GIP and GLP-1 receptors, meaning they activate both pathways. By contrast, MariTide is described as blocking, or antagonising, the GIP receptor while activating the GLP-1 receptor. This antagonist versus agonist distinction at the GIP receptor is the main reason researchers categorise MariTide as a different mechanistic approach, even though both approaches involve the incretin system.
Mechanistic framing only
- Dual-agonist approach: described as activating both GIP and GLP-1 receptors
- MariTide approach: described as blocking the GIP receptor and activating the GLP-1 receptor
- These are structural and pharmacological distinctions, not comparisons of outcomes
Where it sits in development
Publicly available records indicate that MariTide has progressed through earlier-phase studies and into a Phase 3 programme that Amgen refers to under the MARITIME name. This programme includes multiple trial arms across different study populations and was initiated in 2024 and 2025 according to clinical trial registries.
We are deliberately not reproducing efficacy figures, safety outcomes, or result percentages from any trial. Clinical results are the domain of the sponsor, regulators, and peer-reviewed publications, and interpreting them is a matter for qualified clinicians. What can be stated neutrally is simply that the candidate is in active late-stage clinical investigation and is not a finished, approved product.
Regulatory status in Australia
MariTide is not approved by the Therapeutic Goods Administration and is not listed on the Australian Register of Therapeutic Goods. It is an investigational candidate. That means it has not been authorised for general supply, prescription, or therapeutic use in Australia.
Any reference material supplied in connection with this molecule is provided strictly for research and educational purposes. Nothing on this page should be read as an offer or suggestion to use the molecule in people, nor as any form of dosing, protocol, or treatment guidance.
Where NovaPeptides references compounds of this kind, it is research-use-only context. No human use, no protocols, and no therapeutic claims are made or implied.
Why it draws pipeline interest
MariTide attracts attention in the 2026 research conversation for a few neutral reasons. Its antibody-peptide conjugate structure is unusual compared with the smaller molecules that dominate the field. Its mechanism combines receptor antagonism and agonism rather than dual agonism. And it has been studied with infrequent dosing intervals, which is a point of scientific interest in how long-acting conjugates are designed.
These are reasons the candidate is discussed by researchers and observers. They are not endorsements, predictions, or claims about performance. Whether the candidate ultimately reaches approval in any country, including Australia, depends on the completion of trials and regulatory review that are still underway.
Key takeaways
The short version
- MariTide is Amgen's maridebart cafraglutide, also known as AMG 133
- It is a bispecific antibody-peptide conjugate, not a standalone peptide
- Its mechanism is described as GIP receptor antagonism plus GLP-1 receptor agonism
- It is in active late-stage clinical investigation under the MARITIME programme
- It is not TGA-approved and is not on the ARTG
- Any reference here is research and educational context only
Frequently asked questions
Is MariTide approved in Australia?+
No. MariTide, or maridebart cafraglutide, is not approved by the Therapeutic Goods Administration and is not listed on the Australian Register of Therapeutic Goods. It is an investigational candidate in clinical development.
Is MariTide a peptide?+
Not in the simple sense. The published literature describes it as a bispecific antibody-peptide conjugate, meaning a monoclonal antibody component joined to peptide components. It is more accurate to describe it as an antibody-peptide conjugate than as a plain peptide.
What is the difference between MariTide and a dual-agonist candidate?+
In neutral mechanistic terms, some dual candidates are described as activating both the GIP and GLP-1 receptors. MariTide is described as blocking the GIP receptor while activating the GLP-1 receptor. The antagonist versus agonist distinction at the GIP receptor is the main structural difference.
What development stage is MariTide at?+
Clinical trial registries indicate it has progressed into a Phase 3 programme that Amgen refers to as MARITIME, with multiple arms initiated in 2024 and 2025. It can be described neutrally as being in active late-stage clinical investigation.
Who develops MariTide?+
MariTide is developed by Amgen. It is also known as maridebart cafraglutide and by the earlier development code AMG 133.
Does NovaPeptides sell MariTide for personal use?+
No. Any reference to compounds of this kind is provided for research and educational purposes only. No human use, dosing, protocols, or therapeutic claims are made or implied.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp